blindness and tirzepatide Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort tirzepatide blindness risk Although rare,

doi: 10.1002/ibd.20903 197 MachielsKJoossensMSabinoJPreterVDArijsIEeckhautVet al

Less common but more serious risks include gallbladder disease and pancreatitis

Understanding the complexities of this medication, including cost factors and potential savings strategies, is essential for anyone contemplating its use

Molecules 12 , 22 (2017)

Synergistic Stack #2: Injury Recovery & Healing For accelerated healing of muscle, tendon, or joint injuries: IGF-1 LR3: 30 mcg once daily for 4 weeks BPC-157: 250 mcg 2x/day for 4-6 weeks (use our BPC-157 calculator) TB-500: 5 mg 2x/week for 4-6 weeks Synergy: IGF-1 LR3 promotes muscle cell growth, BPC-157 supports vascular and epithelial healing, TB-500 enhances cellular migration and tissue repair

Split dosing Some researchers divide their weekly dose into two injections